Weight Management

Latest News

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

December 20th 2024

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose / image credit: ©New Africa/AdobeStock
Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

December 17th 2024

Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose / image credit: ©New Africa/AdobeStock
Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose

December 16th 2024

Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose / image credit: ©New Africa/AdobeStock
Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose

December 12th 2024

More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock
More than Half of US Adults Eligible for Semaglutide: Daily Dose

December 9th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.